Experimental CAR-T therapy targets tough blood cancers in tiny early trial
Disease control
Completed
This early-phase study tested a new cell therapy called RD13-02 in just 2 people with relapsed or refractory CD7-positive blood cancers (like T-cell leukemia or lymphoma). The treatment uses specially engineered immune cells to attack cancer cells. The main goals were to check sa…
Phase: EARLY_PHASE1 • Sponsor: MEI HENG • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC